DEEFIELD, IL--(Marketwired - March 05, 2014) - Horizon Pharma, Inc. (NASDAQ: HZNP) today announced the appointment of Robert F. Carey as executive vice president and chief business officer, bringing a broad base of healthcare investment banking experience. Mr. Carey has assisted biotech and specialty pharma companies raise more than $10 billion in initial public offerings, follow-on offerings, debt offerings and private placements. He has also served as a financial advisor on mergers, acquisitions and strategic alliance transactions with a total deal value of more than $3 billion.
"Bob's tremendous industry and deal-making experience will be invaluable to us as we look to expand our business through acquisitions of products and companies," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma. "With our focus on acquiring additional innovative medicines or companies that complement our products and leverage our commercial infrastructure, Bob is a key addition to our executive team."
Prior to joining Horizon, Mr. Carey spent more than 11 years as managing director and head of the life sciences investment banking group at JMP Securities LLC, a full-service investment bank. Prior to JMP, Mr. Carey was a managing director in the healthcare groups at Dresdner Kleinwort Wasserstein and Vector Securities. Mr. Carey also has held roles at Red Hen Bread, InStadium, Shearson Lehman Hutton and Ernst & Whinney.
Mr. Carey holds a bachelor's degree from the University of Notre Dame.
About Horizon Pharma
Horizon Pharma, Inc. is a commercial stage, specialty pharmaceutical company that markets DUEXIS®, RAYOS®/LODOTRA® and VIMOVO®, which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The Company's strategy is to develop, acquire or in-license additional innovative medicines where it can execute a targeted commercial approach among specific target physicians such as primary care physicians, orthopedic surgeons, and rheumatologists, while taking advantage of its commercial strengths and the infrastructure the Company has put in place. For more information, please visit www.horizonpharma.com.
Robert J. De Vaere
Executive Vice President, Chief Financial Officer
E. Blair Clark-Schoeb